IP Library › Granted Patent US 11,229,637
Granted Patent B2
US 11,229,637 · App. 16/818,800 · Granted Jan 25, 2022

Nitrogen-containing heteroaryl compounds and methods of use thereof

Inventors: Michael P. Arend (Foster City, CA); Lee A. Flippin (Woodside, CA); Volkmar Guenzler-Pukall (San Leandro, CA); Wen-Bin Ho (Los Altos, CA); Eric D. Turtle (Belmont, CA); Xiaohui Du (Foster City, CA)
Assignee: FibroGen, Inc.
A61K31/472A61K31/473A61K31/4725A61K38/1816C07D217/26C07D221/08C07D401/04C07D401/06C07D401/12C07D403/12C07D217/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,229,637
App. No.
16/818,800
Granted
Jan 25, 2022
Kind
B2
Abstract

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

Claims (14)

1. A method of treating anemia associated with chronic kidney disease in a patient undergoing dialysis, comprising administering to the patient a therapeutically effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the patient has been diagnosed with hypertension.

3. The method of claim 1 , wherein the patient has been diagnosed with diabetes.

4. A method of treating anemia associated with chronic kidney disease in a patient undergoing dialysis, comprising administering to the patient a therapeutically effective amount of a compound of formula:

5. The method of claim 4 , wherein the patient has been diagnosed with hypertension.

6. The method of claim 4 , wherein the patient has been diagnosed with diabetes.

7. A method of treating anemia associated with chronic kidney disease in a patient who is not undergoing dialysis, comprising administering to the patient a therapeutically effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the patient has been diagnosed with hypertension.

9. The method of claim 7 , wherein the patient has been diagnosed with diabetes.

10. A method of treating anemia associated with chronic kidney disease in a patient who is not undergoing dialysis, comprising administering to the patient a therapeutically effective amount of a compound of formula:

11. The method of claim 10 , wherein the patient has been diagnosed with hypertension.

12. The method of claim 10 , wherein the patient has been diagnosed with diabetes.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2021
From: AREND, MICHAEL P.; FLIPPIN, LEE A.; GUENZLER-PUKALL, VOLKMAR; HO, WEN-BIN; TURTLE, ERIC D.; DU, XIAOHUI
To: FIBROGEN, INC.
Reel/Frame 055536/0188 →
Continuity (13)
Continuation 16109562 · Aug 22, 2018
Continuation 15133104 · Apr 19, 2016
Continuation 14284325 · May 21, 2014
Continuation 13912483 · Jun 7, 2013
Continuation 13599161 · Aug 30, 2012
Continuation 13186351 · Jul 19, 2011
Continuation 12015275 · Jan 16, 2008
Division 10861082 · Jun 4, 2004
Provisional Application 60476519 · Jun 6, 2003
Provisional Application 60476633 · Jun 6, 2003
Provisional Application 60476420 · Jun 6, 2003
Provisional Application 60476811 · Jun 6, 2003
Related Publication 20210060000A1 · Mar 4, 2021